We investigate how the immune system recognises and responds to cancer, enabling a mechanistic understanding for the development of new therapies for patients.
We investigate the MHC class I antigen processing and presentation pathways. Our focus is on the aminopeptidases ERAP1 and ERAP2, and Tapasin. We are interested in the roles they play in editing the repertoire of peptides presented at the cell surface for recognition by CD8+ T cells and NK cells.
Understanding the principles behind key events in the MHC class I antigen processing pathway provides insights into how and why tumours escape immune detection and how we can reverse this process. Our research helps us to identify tumour antigens, uncovering neo-epitopes, through the development of antigen discovery pipelines. These are vital in generating new cancer therapies and translating neoantigens into vaccines.
We collabourate with biological sciences and chemistry researchers at the university, and around the world. Our collaborations enable:
We work along side our collabourators to investigate a broad specturm of themes, including:
The following postgraduate research projects are open for applications.
